文献速递消化、代谢与肾脏急症

2012—2017年美国商业保险患者初始阿片类处方趋势

Initial Opioid Prescriptions among U.S. Commercially Insured Patients, 2012-2017.
PubMed 文献 · N Engl J Med · 2019-01-01
一句话结论2012年7月至2017年12月美国商业保险未使用阿片类人群中初始阿片类处方月发生率下降54%,但部分处方者仍持续开具长疗程或高剂量高风险初始处方。

该研究利用美国Blue Cross-Blue Shield Axis行政理赔数据,估计2012年7月至2017年12月每月未使用阿片类参保者中初始阿片类处方的发生率,并分析长疗程或高剂量初始处方的比例及处方者数量变化。样本共63,817,512名未使用阿片类参保者(每月平均15,897,673人)。初始阿片类处方月发生率从2012年7月的1.63%降至2017年12月的0.75%,下降54%;启动阿片类治疗的处方者数量从114,043人降至80,462人。但在持续启动治疗的医生亚组中,高风险处方(超过3天供应量或每日剂量≥50吗啡毫克当量)仍以每月每15,897,673名未使用阿片类参保者115,378张处方的速率持续存在。

要点

  • 未使用阿片类参保者中初始阿片类处方月发生率从2012年7月的1.63%降至2017年12月的0.75%,下降54%。
  • 启动阿片类治疗的处方者数量从2012年7月的114,043人降至2017年12月的80,462人。
  • 高风险初始处方定义为超过3天供应量或每日剂量≥50吗啡毫克当量。
  • 在持续启动治疗的医生亚组中,高风险初始处方仍以每月每15,897,673名未使用阿片类参保者115,378张的速率持续存在。
  • 研究样本共63,817,512名未使用阿片类参保者,每月平均15,897,673人。

适用人群与场景

  • 美国商业保险参保者中未使用阿片类的人群,即给定月份前6个月内无阿片类处方且无阿片类使用障碍诊断。
  • 研究场景为行政理赔数据分析,非急诊或ICU床旁直接干预。

诊断标准与关键阈值

  • 未使用阿片类定义为给定月份前6个月内无阿片类处方且无阿片类使用障碍诊断。
  • 高风险初始处方定义为超过3天供应量或每日剂量≥50吗啡毫克当量。

研究设计与关键结果

  • 研究类型为基于美国行政理赔数据的回顾性分析,样本共63,817,512名未使用阿片类参保者,每月平均15,897,673人。
  • 初始阿片类处方月发生率从2012年7月的1.63%降至2017年12月的0.75%,下降54%。
  • 启动阿片类治疗的处方者数量从2012年7月的114,043人降至2017年12月的80,462人。
  • 在持续启动治疗的医生亚组中,高风险初始处方(超过3天供应量或每日剂量≥50吗啡毫克当量)仍以每月每15,897,673名未使用阿片类参保者115,378张处方的速率持续存在。

证据类型、等级与局限

  • 证据类型:基于行政理赔数据的观察性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 研究提示,尽管初始阿片类处方总数下降,部分处方者仍持续开具超过3天供应量或每日剂量≥50吗啡毫克当量的高风险初始处方,作者认为这一亚组处方者值得关注。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The United States is undergoing a crippling opioid epidemic, spurred in part by overuse of prescription opioids by adults 25 to 64 years of age. Of concern are long-duration and high-dose initial prescriptions, which place the patients and their friends and relatives at heightened risk for long-term opioid use, misuse, overdose, and death.

METHODS: We estimated the incidence of initial opioid prescriptions in each month between July 2012 and December 2017 using administrative-claims data from across the United States (accessed through Blue Cross-Blue Shield [BCBS] Axis); monthly incidence was estimated as the percentage of enrollees who received an initial opioid prescription among those who had not used opioids (i.e., no opioid prescription or a diagnosis of opioid use disorder in the 6 months before a given month). We then estimated the percentage of enrollees initiating opioid therapy who received a long-duration or high-dose initial opioid prescription in each month during this period. We also calculated the number of providers who initiated opioid therapy in any patient who had not used opioids in each month and examined monthly trends in the duration and dose of initial opioid prescriptions in prescriber and patient subgroups. Our study sample included 63,817,512 enrollees who had not used opioids (mean, 15,897,673 per month).

RESULTS: The monthly incidence of initial opioid prescriptions among enrollees who had not used opioids declined by 54%, from 1.63% in July 2012 to 0.75% in December 2017. This decline was accompanied by a decreasing number of providers (from 114,043 in July 2012 to 80,462 in December 2017) who initiated opioid therapy in any patient who had not used opioids. Nonetheless, among the shrinking subgroup of physicians who initiated opioid therapy in such patients, high-risk prescribing (i.e., prescriptions for more than a 3-day supply or for a dose of 50 morphine milligram equivalents per day or higher) persisted at a monthly rate of 115,378 prescriptions per 15,897,673 enrollees who had not used opioids.

CONCLUSIONS: As the opioid crisis progressed between July 2012 and December 2017, many providers stopped initiating opioid therapy. Although the number of initial opioid prescriptions declined, a subgroup of providers continued to write high-risk initial opioid prescriptions. (Funded by the National Institute on Aging and a gift from Owen and Linda Robinson.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Zhu W, Chernew ME, Sherry TB, et al. Initial Opioid Prescriptions among U.S. Commercially Insured Patients, 2012-2017. N Engl J Med. 2019. PMID: 30865798. doi:10.1056/NEJMsa1807069

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。